Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Bristol-Myers' Opdivo Study Meets Early Success, Stock Up
by Zacks Equity Research
Bristol-Myers' (BMY) phase III study evaluating Opdivo plus Yervoy successfully met its co-primary endpoints and thus was stopped earlier than expected.
Dow 30 Stock Roundup: UTX to Buy Rockwell Collins, Merck Secures EU Keytruda Approval
by Swarup Gupta
The Dow endured significant losses over a holiday-shortened trading week.
J&J (JNJ) PAH Drug's U.S. Label Expanded for Pediatric Use
by Zacks Equity Research
Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved a label expansion for its oral pulmonary arterial hypertension (PAH) medicine, Tracleer.
Aerie Initiates Phase III Study for Ophthalmic Drug Roclatan
by Zacks Equity Research
Aerie Pharmaceuticals, (AERI) announced that it has commenced phase III study -Mercury 3 in Europe for its pipeline candidate Roclatan 0.02%/0.005%.
Merck's (MRK) Keytruda Gets EU Approval for Bladder Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda received approval in the EU for the first and second line treatment of certain patients with advanced bladder cancer.
MEI Pharma-Presage Biosciences on License Deal for Voruciclib
by Zacks Equity Research
MEI Pharma (MEIP) signs a license contract with Presage Biosciences to develop its CDK inhibitor, voruciclib, by dint of which, it nabs exclusive rights to the oncology candidate.
Pfizer's Acute Leukemia Drug Mylotarg Approved by the FDA
by Zacks Equity Research
Pfizer's (PFE) Mylotarg received FDA nod as a treatment for new or relapsed CD33-positive acute myeloid leukemia.
Key FDA Regulatory Events to Watch Out for in Sep 2017
by Arpita Dutt
Will the FDA follow the recommendation of its advisory panel and give its nod to Amgen (AMGN) and Mylan's biosimilars?
Why Is Pfizer (PFE) Up 2.5% Since the Last Earnings Report?
by Zacks Equity Research
Pfizer (PFE) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Medicines Company's Infection Drug Vabomere Gets FDA Nod
by Zacks Equity Research
The Medicines Company's (MDCO) infection-resistant antibiotic Vabomere secures a fast FDA approval for urinary tract diseases. The drug is likely to hit the market in fourth-quarter 2017.
Pfizer's sNDA for Bosulif Accepted in the U.S. and Europe
by Zacks Equity Research
Pfizer (PFE) along with Avillion announced that the regulatory authorities in the U.S. and Europe have accepted the application for label expansion of Bosulif to include newly diagnosed patients.
Merck's CETP Inhibitor Reduces Cardiovascular Risk by 9%
by Zacks Equity Research
Detailed results from Merck's (MRK) REVEAL study on anacetrapib, showed that the CETP inhibitor and a statin reduced the risk of major coronary events by 9% relative to placebo.
Pfizer Presents Encouraging Eliquis Results in NVAF Patients
by Zacks Equity Research
Pfizer (PFE) and partner Bristol-Myers presented data on Eliquis which showed the potential of the drug in reducing stroke and systemic embolism in NVAF patients undergoing cardioversion.
Biogen Alzheimer's Drug Shows Promise in Long-Term Study
by Zacks Equity Research
Biogen (BIIB) announced data from a long-term study on its Alzheimer's disease candidate, aducanumab, which showed continued benefit in the rate of amyloid decline.
Sangamo Therapeutics Initiates Dosing in Hemophilia A Study
by Zacks Equity Research
Sangamo Therapeutics (SGMO) and partner Pfizer announced the dosing of first patient in Alta study on Hemophilia A candidate, SB-525.
AstraZeneca's Faslodex Gets FDA Nod in First-Line Setting
by Zacks Equity Research
AstraZeneca (AZN) drug Faslodex receives FDA approval for a label extension for Faslodex in the first-line monotherapy setting for the treatment of advanced breast cancer.
Here's Why Clovis Stock Is Up Almost 60% So Far in 2017
by Zacks Equity Research
Clovis Oncology (CLVS) stock is on the rise. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.
Pfizer's Ibrance in First-Line Combo Breast Cancer Study
by Zacks Equity Research
Pfizer, Inc. (PFE) and six international cancer research groups are collaborating on a combination study to explore the use of Ibrance for first-line treatment of advanced breast cancer.
Immunomedics' Progress in Phase II Cancer Study Encouraging
by Zacks Equity Research
Immunomedics, Inc. (IMMU) announced encouraging interim results from a phase II study on its cancer candidate, labetuzumab govitecan. Shares were up 7% on Monday in response.
Pfizer's (PFE) Besponsa Gets FDA Nod with a Boxed Warning
by Zacks Equity Research
Pfizer, Inc.'s (PFE) leukemia candidate, Besponsa received FDA approval, though with a boxed warning on the label.
The Zacks Analyst Blog Highlights: Pfizer, TJX Companies, Honda, American Electric and Novo Nordisk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, TJX Companies, Honda, American Electric and Novo Nordisk
Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo
by Arpita Dutt
Key highlights this week in the pharmaceutical sector include the launch of a drug pricing probe, a resignation from the President's manufacturing council and data on Bristol-Myers' (BMY) Opdivo.
Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx
by Zacks Equity Research
Exelixis, Inc. (EXEL) submitted its supplemental New Drug Application (sNDA) to the FDA for Cabometyx tablets for patients with previously untreated kidney cancer.
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
by Zacks Equity Research
Pfizer, Inc.'s (PFE) newly approved anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant top-line driver for this New York-based pharma giant.
Top Analyst Reports for Pfizer, TJX Companies & Honda
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), TJX Companies (TJX) and Honda (HMC).